<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033669</url>
  </required_header>
  <id_info>
    <org_study_id>A9011071</org_study_id>
    <nct_id>NCT01033669</nct_id>
  </id_info>
  <brief_title>Assessment Of The Inhalation Profiles Of Four Dry Powder Inhalers In Patients With Variable Degrees Of Lung Obstruction</brief_title>
  <official_title>A Randomized Cross-Over Study Investigating The Inhalation Profiles Of Four Dry Powder Inhalation Devices In Subjects With Asthma And Chronic Obstructive Pulmonary Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the inhalation profiles of four dry powder inhalers in patients with variable&#xD;
      degrees of lung obstruction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized to device sequence&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Inspiratory Flow Rate</measure>
    <time_frame>Day 3-10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pressure Slope</measure>
    <time_frame>Day 3-10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Pressure Drop</measure>
    <time_frame>Day 3-10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Pressure Drop</measure>
    <time_frame>Day 3-10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhaled Volume</measure>
    <time_frame>Day 3-10</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">57</enrollment>
  <condition>Asthma</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Dry Powder Inhalers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRC-749</intervention_name>
    <description>There is no drug being used. This is a device.</description>
    <arm_group_label>Dry Powder Inhalers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diskus</intervention_name>
    <description>There is no drug being used. This is a device.</description>
    <arm_group_label>Dry Powder Inhalers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Twisthaler</intervention_name>
    <description>There is no drug being used. This is a device.</description>
    <arm_group_label>Dry Powder Inhalers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Miat Monohaler</intervention_name>
    <description>There is no drug being used. This is a device.</description>
    <arm_group_label>Dry Powder Inhalers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Asthma and COPD patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with a physician documented history or diagnosis of asthma for at least 6&#xD;
             months&#xD;
&#xD;
          -  Reversibility, defined as an increase in FEV1 at the Screening visit of greater than&#xD;
             or equal to 12% and 200 mL&#xD;
&#xD;
          -  Subjects with a physician documented history or diagnosis of mild or severe Chronic&#xD;
             Obstructive Pulmonary Disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects who are pregnant&#xD;
&#xD;
          -  Subjects who have a history of life-threatening asthma/COPD or who have experienced&#xD;
             two or more exacerbations requiring hospitalization in the 12 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Evidence of lower respiratory tract infection&#xD;
&#xD;
          -  Subjects diagnosed with pulmonary fibrosis, bronchiectasis, pneumoconiosis,&#xD;
             sarcoidosis or tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9011071&amp;StudyName=Assessment%20Of%20The%20Inhalation%20Profiles%20Of%20Four%20Dry%20Powder%20Inhalers%20In%20Patients%20With%20Variable%20Degrees%20Of%20Lung%20Obstruction</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>March 15, 2010</last_update_submitted>
  <last_update_submitted_qc>March 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Inhalation profiles</keyword>
  <keyword>asthma</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

